首页> 美国卫生研究院文献>BMC Nephrology >Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass
【2h】

Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass

机译:透析液降钠(SoLID)试验的原理和设计:血液透析期间低透析液钠浓度与标准透析液钠浓度降低左室重量的随机对照试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe current literature recognises that left ventricular hypertrophy makes a key contribution to the high rate of premature cardiovascular mortality in dialysis patients. Determining how we might intervene to ameliorate left ventricular hypertrophy in dialysis populations has become a research priority. Reducing sodium exposure through lower dialysate sodium may be a promising intervention in this regard. However there is clinical equipoise around this intervention because the benefit has not yet been demonstrated in a robust prospective clinical trial, and several observational studies have suggested sodium lowering interventions may be deleterious in some dialysis patients.
机译:背景技术目前的文献认识到,左心室肥大是导致透析患者高心血管疾病过早死亡的重要原因。确定我们如何干预以改善透析人群的左心室肥大已经成为研究的重点。在这方面,通过降低透析液钠的钠暴露量可能是有希望的干预措施。但是,这种干预措施存在临床平衡,因为尚未在可靠的前瞻性临床试验中证明其益处,而且一些观察性研究表明,降低钠盐的干预措施可能对某些透析患者有害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号